India to Cameroon: Albendazole Export Trade Route

To import Albendazole formulations into Cameroon, the following approvals and registrations are necessary:

• Product Registration: All pharmaceutical products must be registered with the National DRA before importation. The registration process involves submitting a comprehensive dossier that includes:
• Administrative information about the applicant and manufacturer.
• Quality documentation detailing the composition, manufacturing process, and quality control measures.
• Non-clinical and clinical data supporting the product's safety and efficacy.

• Dossier Format: The Common Technical Document (CTD) format is typically required for submissions. This standardized format facilitates the review process and ensures consistency in the information provided.

• Approval Timelines: The review and approval process can vary but generally takes several months. Applicants should plan accordingly and submit their dossiers well in advance to accommodate potential delays.

• Product Registration Fees: Fees are applicable for product registration. While specific amounts may vary, applicants should be prepared to cover costs associated with the evaluation and processing of their submissions.

• GMP Inspection Requirements: The National DRA mandates Good Manufacturing Practice (GMP) compliance for all pharmaceutical products. Indian manufacturing facilities producing Albendazole formulations intended for the Cameroonian market must:
• Provide a valid GMP certificate issued by the regulatory authority in India.
• Be prepared for potential inspections by the National DRA to verify compliance with GMP standards.

Indian exporters of Albendazole formulations must adhere to stringent quality and GMP standards to supply the Cameroonian market:

• GMP Certifications: Exporters must hold a valid GMP certificate issued by the Central Drugs Standard Control Organization (CDSCO) in India. This certification confirms that the manufacturing facility complies with international GMP standards.

• Approved Indian Facilities: Manufacturing facilities that have been inspected and approved by the National DRA are eligible to export to Cameroon. It is essential for exporters to maintain up-to-date records of their GMP certifications and any inspections conducted.

• Recent Inspections and Regulatory Actions: As of March 2026, there have been no publicly reported inspections or regulatory actions by the National DRA against Indian pharmaceutical companies supplying Albendazole formulations to Cameroon. However, exporters should remain vigilant and ensure continuous compliance with all regulatory requirements to avoid potential issues.

In the past 18 months, several regulatory developments have impacted Indian pharmaceutical exports to Cameroon:

• Harmonization of Standards: In July 2024, the National DRA announced efforts to harmonize its regulatory standards with international guidelines, including those from the World Health Organization (WHO). This initiative aims to streamline the registration process and enhance the quality of pharmaceutical products imported into Cameroon.

• Introduction of Electronic Submission System: In January 2025, the National DRA implemented an electronic submission system for product registration dossiers. This system is designed to expedite the review process and improve communication between applicants and the regulatory authority.

• Mutual Recognition Agreements: In September 2025, Cameroon entered into a mutual recognition agreement with select countries, including India. This agreement facilitates the acceptance of GMP certificates issued by recognized regulatory authorities, potentially reducing the need for redundant inspections and expediting the approval process for Indian exporters.

These developments reflect Cameroon's commitment to enhancing its regulatory framework and fostering international trade in pharmaceutical products.

As of 2024, the global Albendazole market was valued at over USD 0.6 billion, with a projected compound annual growth rate (CAGR) of approximately 4% from 2025 to 2030. While specific data for Cameroon is limited, the country's demand for Albendazole formulations is driven by the high prevalence of parasitic infections, particularly soil-transmitted helminths and lymphatic filariasis. Mass drug administration (MDA) programs, often supported by international health organizations, have been instrumental in addressing these health challenges.

Cameroon's healthcare expenditure has been increasing, reflecting a commitment to improving public health infrastructure and access to essential medicines. However, domestic production of Albendazole formulations is minimal, necessitating reliance on imports to meet national demand.

Pharmaceutical imports under HS code 30049099 into Cameroon are subject to an MFN import duty rate of 5%. Additionally, these products are exempt from VAT, reducing the overall cost burden on importers and consumers. There are no specific Free Trade Agreements (FTAs) between India and Cameroon that further affect pharmaceutical tariffs. Currently, there are no anti-dumping duties imposed on Albendazole formulations imported into Cameroon.

India is a significant supplier of Albendazole formulations to Cameroon, accounting for 3.9% of India's total Albendazole formulation exports, valued at $2.8 million USD across 163 shipments from 55 Indian manufacturers/exporters. The top Indian exporters include Krosyl Pharmaceuticals Private Limited ($1.7M), Zee Laboratories ($0.2M), Lanark Laboratories Pvt Ltd ($0.1M), Micro Labs Limited ($0.1M), and Globela Pharma Private Limited ($0.1M).

Other major countries supplying Albendazole to Cameroon include China and various European Union (EU) member states. India's competitive pricing, coupled with the exemption from VAT and a relatively low import duty, enhances its attractiveness as a supplier compared to competitors. The strategic use of ports such as Nhava Sheva Sea (INNSA1), JNPT, and Sonepat ICD facilitates efficient logistics and distribution channels, further strengthening India's position in the Cameroonian market.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2024. This extensive manufacturing capability extends to Albendazole formulations, including tablets, capsules, and syrups. The country's cost-effective production is driven by economies of scale, competitive labor costs, and a well-established supply chain. As of 2025, India boasts over 1,400 WHO-GMP certified facilities and more than 800 US FDA-approved manufacturing sites, ensuring compliance with stringent international quality standards. Notably, in September 2024, Alembic Pharmaceuticals received final approval from the US FDA for its Albendazole Tablets USP, 200 mg, underscoring India's capability to meet global regulatory requirements.

When comparing Albendazole formulations from India, China, and the European Union, several factors emerge:

• Cost: As of February 2026, the price of Albendazole in India was approximately $21.75 per kilogram, reflecting a 0.3% decrease from previous months. Chinese manufacturers offer competitive pricing, though specific figures vary. European producers typically have higher costs due to stringent regulatory environments and higher production expenses.

• Quality Perception: Indian pharmaceutical companies have a strong reputation for producing high-quality generic medicines, with numerous facilities holding WHO-GMP and US FDA certifications. Chinese manufacturers have made significant strides in quality but may face perceptions of inconsistency. European manufacturers are often associated with premium quality but at higher price points.

• Regulatory Acceptance in Cameroon: Cameroon's regulatory authorities recognize and accept WHO-GMP and US FDA certifications, which many Indian manufacturers possess, facilitating smoother importation processes.

• Supply Reliability: Indian manufacturers have a proven track record of reliable supply chains, supported by robust infrastructure and experience in global distribution. Chinese suppliers have improved reliability but may still encounter challenges related to regulatory compliance and logistics. European suppliers are reliable but may have longer lead times and higher costs.

The India-Cameroon supply chain for Albendazole formulations is robust, supported by India's substantial manufacturing capacity and advanced packaging facilities. Indian manufacturers have demonstrated consistent compliance with international regulatory standards, including WHO-GMP and US FDA approvals. For instance, in November 2025, Granules India Limited's subsidiary, Granules Life Sciences, received its first US FDA approval for a product manufactured at its Hyderabad facility, indicating ongoing expansion and adherence to quality standards. There have been no significant supply disruptions reported in recent years, and leading manufacturers continue to invest in capacity expansion to meet global demand.

For Cameroonian buyers sourcing Albendazole formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure consistent product availability.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers; negotiating favorable terms based on projected demand is advisable.

• Payment Terms: Standard payment terms in India-Cameroon pharmaceutical trade often include letters of credit or advance payments; understanding and negotiating these terms is crucial.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits, verification of regulatory certifications (such as WHO-GMP and US FDA approvals), and assessment of past performance records.

• Regulatory Compliance: Ensure that selected suppliers comply with both Indian and Cameroonian regulatory requirements to facilitate smooth importation and distribution processes.

Before engaging with an Indian supplier for Albendazole formulations, Cameroon buyers should adhere to the following pre-qualification steps:

1. Verify National Drug Regulatory Authority (DRA) Registration: Confirm that the supplier's products are registered with Cameroon's DRA, ensuring compliance with local pharmaceutical regulations.

2. Assess Good Manufacturing Practice (GMP) Certification: Obtain a valid GMP certificate from the supplier, issued by a recognized authority, to confirm adherence to international manufacturing standards.

3. Review Drug Master File (DMF): Request the supplier's DMF to evaluate detailed information on the manufacturing process, controls, and stability data of the Albendazole formulations.

4. Evaluate Quality Management Systems: Ensure the supplier has a robust quality management system in place, including standard operating procedures, quality control measures, and compliance with ICH guidelines.

5. Confirm Regulatory Compliance: Check for any recent regulatory actions against the supplier, such as FDA warning letters or WHO-GMP suspensions, which may indicate compliance issues.

6. Assess Export Experience: Determine the supplier's track record in exporting Albendazole formulations to global markets, indicating reliability and experience in international trade.

7. Request Stability Data: Obtain stability data relevant to ICH climatic zones, particularly Zone IVb, which pertains to hot and very humid conditions like those in Cameroon.

8. Plan for Facility Audit: Arrange for an on-site audit of the supplier's manufacturing facility to assess compliance with GMP standards and overall operational integrity.

When sourcing Albendazole formulations from Indian manufacturers, Cameroon buyers should request the following documents:

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs clearance and verifying the authenticity of the product's origin.

3. Good Manufacturing Practice (GMP) Certificate: Issued by a recognized regulatory authority, this certificate confirms that the manufacturing facility complies with GMP standards.

4. Stability Data: Includes studies conducted under ICH guidelines to demonstrate the product's shelf life and stability under various environmental conditions, particularly relevant to ICH Zone IVb.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency in manufacturing.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and other pertinent information about the Albendazole formulation.

7. Free Sale Certificate from CDSCO: Issued by the Central Drugs Standard Control Organization (CDSCO) in India, this certificate indicates that the product is approved for sale in India and is freely sold in the domestic market.

8. Insurance Certificates: Documents confirming that the supplier has adequate insurance coverage for product liability, ensuring protection against potential claims related to product quality or safety.

When evaluating Indian suppliers of Albendazole formulations, be vigilant for the following warning signs:

1. Regulatory Non-Compliance: Recent FDA warning letters or WHO-GMP suspensions indicate serious compliance issues. For instance, in September 2024, Alembic Pharmaceuticals received final FDA approval for Albendazole Tablets USP, 200 mg, demonstrating compliance with stringent regulatory standards.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability data, especially for ICH Zone IVb, raises concerns about the product's suitability for Cameroon's climatic conditions.

4. Limited Export History: Suppliers without a proven track record of exporting Albendazole formulations to regulated markets may lack the necessary experience and reliability.

5. Resistance to Audits: Suppliers unwilling to permit facility audits or provide transparent information about their manufacturing processes should be approached with caution.

Conducting thorough audits and maintaining ongoing monitoring are crucial for ensuring the quality and compliance of Albendazole formulations sourced from Indian manufacturers:

1. Pre-Audit Desktop Review: Evaluate the supplier's documentation, including GMP certificates, DMFs, and previous audit reports, to identify potential areas of concern before the on-site visit.

3. Post-Audit Corrective Actions: Document any deficiencies identified during the audit and agree on a corrective action plan with the supplier, including timelines for resolution.

4. Annual Re-Qualification Process: Implement a yearly review of the supplier's performance, including follow-up audits and assessment of any changes in their operations or regulatory status.

5. Remote Monitoring Options: Utilize virtual audits, regular video conferences, and electronic document reviews to maintain oversight between on-site visits.

By adhering to these guidelines, Cameroon buyers can ensure the selection of reliable and compliant Indian suppliers for Albendazole formulations, safeguarding product quality and patient safety.